MabThera

January 29, 2018January 29, 2018

Pfizer’s Rituxan Biosimilar Equally Effective at Treating Follicular Lymphoma, Trial Shows

News

Pfizer‘s biosimilar therapy candidate PF-05280586 has shown equal effectiveness as Rituxan (rituximab) at treating indolent follicular lymphoma in a Phase 3 trial, the company announced. Indolent, or slow-growing, follicular lymphoma ... Read more

September 26, 2017September 26, 2017

European Commission Approves Gazyvaro as First-Line Follicular Lymphoma Therapy

News

The European Commission has approved Roche’s Gazyvaro (obinutuzumab) for previously untreated patients with advanced follicular lymphoma. The treatment is approved in combination with chemotherapy and should be followed by Gazyvaro maintenance ... Read more

April 28, 2017April 28, 2017

Sandoz Biosimilars Rituximab and Etarnercept Move One Step Closer to EU Approval

News

Sandoz, a division of Swiss pharmaceutical giant Novartis, welcomed the April 21 decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend ... Read more

August 1, 2016August 1, 2016

Revlimid Fails to Improve Overall Survival of Diffuse Large B-Cell Lymphoma For Certain Patients

News

Patients with diffuse large B-cell lymphoma (DLBCL) who respond to first line Rituxan/Mabthera (rituximab) plus CHOP chemotherapy (R-CHOP) induction therapy may have increased progression-free survival when treated with Revlimid ... Read more

May 3, 2016May 3, 2016

CHMP Supports EU Approval of Obinutuzumab (Gazyvaro) to Treat Follicular Lymphoma

News

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy and then as monotherapy, to treat select patients with follicular lymphoma. The recommendation is as treatment ... Read more

Pin It on Pinterest